Julie Vose, MD, MBA, on COVID-19 and Cancer Care
The lymphoma expert, from the University of Nebraska Medical Center, spoke about how the COVID-19 pandemic has affected her facility and their ability to perform cancer care.
Julie Vose, MD, MBA, chief of the oncology and hematology division in the Department of Internal Medicine at the University of Nebraska Medical Center (UNMC), discussed the coronavirus disease 2019 (COVID-19) pandemic in an interview with CancerNetwork®.
Vose, also the editor-in-chief for the journal Oncology, indicated that though the virus has not yet impacted her particular facility in a severe way, they are still prepared for the possibility. Additionally, similar to many other cancer treatment centers, Vose highlighted the need to keep patients with cancer out of the hospital as much as possible. She suggested that at the UNMC facility, they have begun utilizing telehealth to keep patients out of the clinic and postponing treatment to the extent that they safely can.
“We’re really only seeing patients who are on active therapy, having problems, or really need to be seen,” said Vose. “And that’s for the safety of the patients and also for the safety of the healthcare workers.”
Vose also suggested that if there is 1 good thing to have come out of this pandemic, it is the ability for patients to utilize telehealth. It is her hope that moving forward, this becomes a regular facet of medical practices.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences National Broadcast, airing daily on all MJH Life Sciences channels.
Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment
July 6th 2020The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.
Despite Increased Use of Telemedicine for Cancer Care During COVID-19, Disparities Persist
May 26th 2022The findings of this retrospective study of more than 25,000 patients with cancer newly diagnosed during the COVID-19 pandemic highlight a need to reduce the inequities in telemedicine use for cancer care, according to the study’s lead author.
What Do American Board of Internal Medicine Recertification Exams Measure?
April 7th 2022Julie M. Vose, MD, MBA, chief of Hematology/Oncology at the Buffett Cancer Center of the University of Nebraska Medical Center, writes about American Board of Internal Medicine Recertification Exams in her monthly "Letter to the Readers."
